Garri Zmudze Insights

CONTRIBUTED CONTENT

Garri contributes op-eds and original content for leading outlets across web3, health, startups, and more.

AgeTech World: Longevity Will Never Be a Magic Pill That Will Make Us Younger

I share my drive and LongeVC's strategic investments in advancing an ageless future, emphasising the need for standardised longevity practises and systemic health economics reform
Contributed Content
·
3 min
·
November 7, 2023
AgeTech World: Longevity Will Never Be a Magic Pill That Will Make Us Younger

Clinical Leader: Future Funding, Trial Success Necessitates Use Of AI

AI is markedly transforming clinical trials, from enhancing predictive capabilities and patient adherence insights to optimizing trial design and expediting drug development.
Contributed Content
·
1 min
·
October 16, 2023
Clinical Leader: Future Funding, Trial Success Necessitates Use Of AI

Clinical Leader: Decentralization, it's more than you think

Decentralization encourages transparency, inclusion, and new funding streams for clinical research.
Contributed Content
·
3 min
·
August 2, 2023
Clinical Leader: Decentralization, it's more than you think

EXPERT COMMENTARY

Garri is a leading voice for trending topics in the field of health and investing.

Labiotech.eu: Gold rush over: What happens to biotech now that venture capital is out of reach?

Garri shares insights on the current state of biotech venture capital, including overvaluations, recent deals, and the impact of events like the SVB collapse.
Expert Commentary
·
2 min
·
Jul 27
Labiotech.eu: Gold rush over: What happens to biotech now that venture capital is out of reach?

Clinical Leader: Decentralization, it's more than you think

Decentralization encourages transparency, inclusion, and new funding streams for clinical research.
Expert Commentary
·
6 min
·
Jul 27
Clinical Leader: Decentralization, it's more than you think

Clinical Leader: Future Funding, Trial Success Necessitates Use Of AI

AI is markedly transforming clinical trials, from enhancing predictive capabilities and patient adherence insights to optimizing trial design and expediting drug development.
Expert Commentary
·
1 min
·
Jul 27
Clinical Leader: Future Funding, Trial Success Necessitates Use Of AI

ANNOUNCEMENT

Stay up-to-date with the latest from Garri and the companies within his realm.

Longevity.Technology: The time is right for specialist Longevity investment

Garri Zmudze, Sergey Jakimov, and Ilya Suharenko launch a new fund for longevity research: LongeVC.
Announcements
·
2 min
·
Jul 27
Longevity.Technology: The time is right for specialist Longevity investment

Longevity.Technology: Basepaws acquisition – exploring longevity beyond human health

Garri was an angel investor in pet health company Basepaws. Its acquisition offers promising insights into the future of human longevity.
Announcements
·
7 min
·
Jul 27
Longevity.Technology: Basepaws acquisition – exploring longevity beyond human health

ARDD: Decentralized science and blockchain in aging research

Garri explains the Longevity Science Foundation's work as a nonprofit supporting a decentralized and transparent future of longevity research.
Announcements
·
4 min
·
Jul 27
ARDD: Decentralized science and blockchain in aging research

ALL RESOURCES

Content at the cutting-edge of health and technology.

Sifted: Purrsonalised health: The startups and VCs betting on pet genetics

Animal genetics market revenue is predicted to exceed $6.4bn by 2027. Here are some of the pet genetics startups to watch.
Expert Commentary
·
1 min
·
Jul 27
Sifted: Purrsonalised health: The startups and VCs betting on pet genetics

Green Market Report: Can psychedelics combat aging in humans?

Longevity researchers are looking to psychedelics as an avenue for unlocking new understanding about aging and brain health.
Expert Commentary
·
2 min
·
Jul 27
Green Market Report: Can psychedelics combat aging in humans?

Labiotech.eu: 5 reasons why collaboration is important in research

Collaboration in biotech will drive the future of the industry. Nonprofits, VCs, and startups must cooperate for success.
Expert Commentary
·
7 min
·
Jul 27
Labiotech.eu: 5 reasons why collaboration is important in research

Forbes: Meet a VC on a mission to support women in longevity

Garri leads LongeVC to invest in diverse founders that will ensure a representative future of longevity and biotech.
Expert Commentary
·
2 min
·
Jul 27
Forbes: Meet a VC on a mission to support women in longevity

Labiotech.eu: Gold rush over: What happens to biotech now that venture capital is out of reach?

Garri shares insights on the current state of biotech venture capital, including overvaluations, recent deals, and the impact of events like the SVB collapse.
Expert Commentary
·
2 min
·
Jul 27
Labiotech.eu: Gold rush over: What happens to biotech now that venture capital is out of reach?

Clinical Leader: Decentralization, it's more than you think

Decentralization encourages transparency, inclusion, and new funding streams for clinical research.
Expert Commentary
·
6 min
·
Jul 27
Clinical Leader: Decentralization, it's more than you think

Clinical Leader: Future Funding, Trial Success Necessitates Use Of AI

AI is markedly transforming clinical trials, from enhancing predictive capabilities and patient adherence insights to optimizing trial design and expediting drug development.
Expert Commentary
·
1 min
·
Jul 27
Clinical Leader: Future Funding, Trial Success Necessitates Use Of AI

AgeTech World: Longevity Will Never Be a Magic Pill That Will Make Us Younger

I share my drive and LongeVC's strategic investments in advancing an ageless future, emphasising the need for standardised longevity practises and systemic health economics reform
Expert Commentary
·
4 min
·
Jul 27
AgeTech World: Longevity Will Never Be a Magic Pill That Will Make Us Younger

Wall Street Journal: The Clues to Longer Life That Are Coming From Dogs

Scientists are researching dog aging, including supplement trials and genetic analysis, to unlock a greater understanding of human longevity.
Expert Commentary
·
1 min
·
Jul 27
Wall Street Journal: The Clues to Longer Life That Are Coming From Dogs

DealStreet Asia: LongeVC Targets $250M for Fund II, Bets on Opportunities in Asia’s Longevity Tech Growth

In a recent interview for DealStreet Asia, Garri discussed the international longevity and biotech investing landscape and provided insights on LongeVC’s planned Fund II.
Expert Commentary
·
2 min
·
Jul 27
DealStreet Asia: LongeVC Targets $250M for Fund II, Bets on Opportunities in Asia’s Longevity Tech Growth
© 2024